PROCEPT BioRobotics Corporation

Aquablation Therapy Shows Comparable Efficacy to Laser Enucleation with Better Sexual Function Preservation in BPH Treatment

2 months ago

• The WATER III randomized clinical trial demonstrated that Aquablation therapy provides similar symptom relief to laser enucleation for treating benign prostatic hyperplasia (BPH) in large prostates (80-180mL). • Patients who underwent Aquablation showed significantly lower rates of ejaculatory dysfunction (14.8% vs 77.1%) and stress incontinence (0% vs 9.1%) compared to those who received laser enucleation treatment. • The three-month data revealed comparable International Prostate Symptom Score improvements between both treatments, though laser enucleation showed greater improvements in urinary flow rate and post-void residual reduction.

Aquablation Demonstrates Long-Term Efficacy and Safety in BPH Patients

6 months ago

• Aquablation shows a significant decrease in IPSS scores by approximately 15 points after 5 years, regardless of prostate size, indicating sustained symptom relief. • The procedure significantly improves Qmax, nearly doubling flow rates from baseline, demonstrating enhanced urinary function over the long term. • Low complication rates and excellent preservation of sexual function highlight the safety profile of Aquablation in treating BPH. • A retreatment rate of less than 4% over 5 years suggests durable outcomes with Aquablation, underscoring its potential as a long-term solution for BPH.

FDA Approves Pivotal Trial of Aquablation Therapy vs. Prostatectomy for Localized Prostate Cancer

8 months ago

• The FDA has approved an IDE trial comparing Aquablation therapy to radical prostatectomy for localized prostate cancer. • The WATER IV PCa trial will enroll 280 patients with Grade Group 1-3 localized prostate cancer across 50 sites. • The study's primary endpoint is morbidity at 6 months, with long-term follow-up on treatment-related harm and oncologic events. • Aquablation, already approved for BPH, aims to improve safety and quality of life outcomes compared to prostatectomy.